Antimicrobial Resistance: A Brief Report

Andrew Neon^*
*Correspondence: Andrew Neon, Centre de Recherche Cardio-Thoracique de Bordeaux, Université Bordeaux, Bordeaux, France, Email:

Introduction

The World Health Organization (WHO) has long recognised the need for a more effective and well-coordinated global response to AMR. The WHO Global Strategy for Antimicrobial Resistance Containment, published in 2001, established a framework of measures to prevent the emergence and spread of antimicrobial-resistant microorganisms. The Evolving Threat of Antimicrobial Resistance –Options for Action was published by WHO in 2012, and it recommended a combination of interventions, including strengthening health systems and surveillance, improving antimicrobial use in hospitals and the community, infection prevention and control, encouraging the development of appropriate new drugs and vaccines, and political commitment.

An antibiotic is a chemical that kills or prevents germs from growing. Antimicrobial medications are classed according to the germs they are most effective against [1]. Antibiotics, for example, are used to treat bacteria; antifungals, on the other hand, are used to cure fungus. They can also be classified according to their function. Microbicides are those that kill germs, whereas bacteriostatic treatments only prevent them from growing. Antimicrobial chemotherapy is the treatment of infection with antimicrobial drugs, whereas antimicrobial prophylaxis is the prevention of infection with antimicrobial medicines [2].

Description

Antimicrobial Resistance (AMR) has emerged as one of the most severe public health concerns of the twenty-first century, posing a threat to the effective prevention and treatment of illnesses caused by bacteria, parasites, viruses, and fungi that are no longer sensitive to standard antibiotics. Antibiotic resistance in bacteria exacerbates the problem of antimicrobial resistance (AMR). Bacteria that cause common or serious infections have evolved resistance to each new antibiotic that has been introduced to the market, to varying degrees, over several decades. When confronted with this reality, fast action is essential to avoid a global health-care crisis.

Following the declaration of surveillance as a primary role, WHO issued the first global report on AMR surveillance in April 2014, compiling data from national and international surveillance networks. Surveillance data can be particularly valuable for orienting treatment options, assessing AMR trends, selecting priority regions for interventions, and monitoring the impact of measures to control resistance, as shown in this research [3]. The lack of adequate surveillance in many regions of the world leaves enormous gaps in our understanding of the phenomenon's distribution and scope.

Antibiotic resistance's influence on mortality and public health costs is difficult to quantify, and few research have been conducted on the subject. Antibiotic-resistant illnesses impact more than two million individuals in the United States each year, according to the US Centers for Disease Control and Prevention (CDC), with at least 23,000 people dying as a result of the infection.

Chemotherapy for cancer treatment, organ transplantation, hip replacement surgery, critical care for pre-term neonates, and many more tasks would be impossible to undertake without efficient antibiotics. In fact, multidrugresistant bacterial infections are one of the leading causes of morbidity and mortality in patients undergoing these treatments. Infections among cancer patients with chemotherapy-related neutropenia have significant antibiotic resistance rates, according to a 2014 paper from the University of Texas. Infections after orthotopic liver transplantation were found to have a significant proportion of antibiotic-resistant bacteria, according to a recent study from the Medical University of Warsaw [4,5].

Future Perspective

Antifungals are drugs that destroy or stop fungus from growing. They're used to treat diseases like athlete's foot, ringworm, and thrush in medicine, and they function by exploiting distinctions between mammalian and fungal cells. Fungi and humans are both eukaryotic, unlike bacteria. As a result, at the molecular level, fungal and human cells are comparable, making it more difficult to locate a target for an antifungal treatment that does not also present in the host organism. As a result, some of these medications have a lot of negative effects. If the medicine is not used properly, some of these adverse effects might be fatal.

Acknowledgement

None.

Conflict of Interest

The author has no conflict of interest towards the article.

References

1. Tenover, Fred C. "Development and spread of bacterial resistance to antimicrobial agents: an overview." Clinical infectious diseases 33, no. Supplement_3 (2001): S108-S115.

Google Scholar, Crossref, Indexed at

2. File Jr, Thomas M. "Overview of resistance in the 1990s." Chest 115, no. 3 (1999): 3S-8S.

Google Scholar, Crossref, Indexed at

3. Acar, J. and B. Rostel. "Antimicrobial resistance: an overview." Rev Sci Tech  20 (2001): 797-810.

Google Scholar, Crossref, Indexed at

4. Kim, Woo J and Seung Chull Park. "Bacterial resistance to antimicrobial agents: an overview from Korea." Yonsei Med J 39 (1998): 488-494.

Google Scholar, Crossref, Indexed at

5. Reygaert, Wanda C. "An overview of the antimicrobial resistance mechanisms of bacteria." AIMS microbiology 4, no. 3 (2018): 482.

Google Scholar, Crossref, Indexed at